An overview of our requirements is outlined below. For more information and proposal submission instructions, refer to the RFP main document. Additional instructions may get published in bulletins.
On December 18th, 2023, the federal government announced the creation of Canada’s Drug Agency (CDA-AMC) by building on the foundation of CADTH and in partnership with provinces and territories. With the creation of the CDA-AMC, the organization now has an expanded mandate—in addition to its core work on HTAs and clinical and cost effectiveness of new drugs—which includes appropriate prescribing and use, data and analytics, and system coordination. Specific to Appropriate Use (AU), CDA-AMC has been tasked with driving a coordinated approach and a common agenda to improve patient safety and outcomes associated with prescribing and use of medications. To do this, CDA-AMC will finalize a pan-Canadian appropriate prescribing and use strategy and develop a corresponding program.
Appropriate use can be defined as follows:
Appropriate use is when patients, caregivers, and health care professionals work together to choose safe and effective medications most suited for that person's needs and goals to achieve best health outcomes. This can be subdivided into three main categories consisting of overuse, underuse and inappropriate use.
To support the development of its pan-Canadian Appropriate Use (AU) Program, CDA-AMC is commissioning the development of a Resource Paper that will identify key areas of focus for AU in a specific context, fill knowledge gaps, establish baseline understanding, and propose actionable, evidence-informed interventions to improve appropriate use. This work aligns with CDA-AMC’s pan-Canadian Appropriate Use Strategy, specifically around our Strategy and Policy strategic priority. The Resource Paper is intended to reflect a pan-Canadian perspective. Written for jurisdictional decision-makers and other healthcare leaders, Resource Papers will build baseline knowledge about appropriate use to help advance policies and programs.
The topic of appropriate use of prescription medications in dental care settings has been selected as the focus of the next Resource Paper. This topic was prioritized through deliberation by CDA-AMC’s Appropriate Use Advisory Committee and consultations with experts, based on its high potential impact to provide decision-makers with a common understanding of appropriate use issues facing dental care Despite the regular use of prescription medications in dentistry, there is limited pan-Canadian understanding of prescribing practices, variations in care, and potential areas of concern related to inappropriate use.
The intended audiences for this Resource Paper include policymakers and decision-makers at the federal, provincial, and territorial levels, as well as health system leaders and healthcare organizations across Canada. The paper will aim to provide these audiences with practical insights and recommendations to guide decision-making, quality improvement, and policy development.
